Patents by Inventor Kenneth A. Koeplinger

Kenneth A. Koeplinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted drug delivery using sulfonamide derivatives
    Patent number: 6653331
    Abstract: The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free —NH— which has been derivatized by the attachment of an electrophile containing a moiety, such as p-CN— or p-NO2-pyridinylsulfonyl groups, or p-NO2- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: November 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Zhiyang Zhao, Alfredo G. Tomasselli, Kenneth A. Koeplinger, Tillie Peterson
  • TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES
    Publication number: 20030109555
    Abstract: The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free —NH— which has been derivatized by the attachment of an electrophile containing a moiety, such as p-CN— or p-NO 2-pyridinylsulfonyl groups, or p-NO 2- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Gluthathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond.
    Type: Application
    Filed: March 17, 1999
    Publication date: June 12, 2003
    Inventors: ZHIYANG ZHAO, ALFREDO G. TOMASSELLI, KENNETH A. KOEPLINGER, TILLIE PETERSON
  • Method for autoactivation of procaspase 8
    Publication number: 20020045205
    Abstract: A novel recombinant procaspase 8 protein lacking the death effector domains and a method for converting said novel procaspase protein to full active human caspase 8 by concentration of the procaspase 8 on a collection device.
    Type: Application
    Filed: May 22, 2001
    Publication date: April 18, 2002
    Inventors: Robert Leroy Heinrikson, Alfredo Giuseppe Tomasselli, Kenneth A. Koeplinger
  • Method for autoactivation of procaspase 8
    Patent number: 6303329
    Abstract: A novel recombinant procaspase 8 protein lacking the death effector domains and a method for converting said novel procaspase protein to full active human caspase 8 by concentration of the procaspase 8 on a collection device.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: October 16, 2001
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert Leroy Heinrikson, Alfredo Giuseppe Tomasselli, Kenneth A. Koeplinger